RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

2022 includes $15,500 in licensing revenue recognized in connection with an amendment of our License Agreement with Santen, effective March 31, 2022, net of a $500 transaction fee expense classified... | May 11, 2023

Related Keywords

United States ,America ,Lisam Wilson ,Brian Markison ,Nasdaq ,Site Communications Inc ,Globenewswire Inc ,Drug Administration ,Exchange Commission ,Alora Pharmaceuticals ,Annual Beauty Awards ,Chief Executive Officer ,Drooping Lid ,Annual Beauty ,Best Innovation ,Annual Report ,Media Relations ,Site Communications ,Financial Tables ,Condensed Consolidated Statements ,Operating Activities ,Investing Activities ,Financing Activities ,License Agreement ,Note Purchase Agreement ,Rvl Pharmaceuticals Plc Stock Exchange ,News ,Information ,Press Release ,022 ,Ncludes ,N ,Icensing ,Revenue ,Ecognized ,Connection ,Ith ,Amendment ,F ,Fur ,License ,Agreement ,Ffective ,Arch ,Pet ,Transaction ,Fee ,Xpense Rvlp Ie00bf2hdl56 ,